Ignyta Inc. (NASDAQ:RXDX)’s share price was down 3.2% during trading on Thursday . The stock traded as low as $5.45 and last traded at $5.50, with a volume of 70,840 shares traded. The stock had previously closed at $5.68.

Several equities analysts have recently commented on RXDX shares. Cantor Fitzgerald reissued a “buy” rating and issued a $18.00 target price on shares of Ignyta in a report on Friday, June 17th. Jefferies Group reissued a “buy” rating and issued a $20.00 target price on shares of Ignyta in a report on Monday, June 6th. Leerink Swann reissued a “buy” rating on shares of Ignyta in a report on Thursday, May 12th. Piper Jaffray Cos. restated a “buy” rating and issued a $32.00 price target on shares of Ignyta in a research report on Sunday, May 8th. Finally, Credit Suisse Group AG restated a “buy” rating on shares of Ignyta in a research report on Tuesday, July 12th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $18.07.

The firm’s market cap is $229.46 million. The firm has a 50 day moving average of $5.49 and a 200 day moving average of $6.97.

Ignyta (NASDAQ:RXDX) last issued its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by $0.11. On average, equities analysts forecast that Ignyta Inc. will post ($2.72) EPS for the current fiscal year.

In other news, Director Alexander W. Casdin acquired 232,000 shares of the company’s stock in a transaction dated Wednesday, May 4th. The shares were acquired at an average price of $6.25 per share, with a total value of $1,450,000.00. Following the purchase, the director now directly owns 100,000 shares of the company’s stock, valued at $625,000. The purchase was disclosed in a legal filing with the SEC, which is available at this link.

Ignyta, Inc is an oncology biotechnology company. The Company focuses on an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. Its Rx is focused on discovering, in licensing or acquiring, then developing and commercializing molecularly targeted therapies that, sequentially or in combination, are foundational for eradicating residual disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.